Fawcett C, Tickle J, Coles C
MAbs. 2024; 16(1):2311992.
PMID: 39674918
PMC: 10883111.
DOI: 10.1080/19420862.2024.2311992.
Ellerman D
BioDrugs. 2024; 39(1):75-102.
PMID: 39673023
DOI: 10.1007/s40259-024-00691-0.
Gu Y, Zhao Q
Mol Diagn Ther. 2024; 28(6):669-702.
PMID: 39172329
PMC: 11512917.
DOI: 10.1007/s40291-024-00734-w.
Mitra A, Kumar A, Amdare N, Pathak R
Biology (Basel). 2024; 13(5).
PMID: 38785789
PMC: 11118874.
DOI: 10.3390/biology13050307.
Inoue T, Yamamoto Y, Sato K, Okemoto-Nakamura Y, Shimizu Y, Ogawa M
iScience. 2024; 27(4):109363.
PMID: 38500835
PMC: 10946335.
DOI: 10.1016/j.isci.2024.109363.
A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis.
Tietz J, Gunde T, Warmuth S, Weinert C, Brock M, Simonin A
JID Innov. 2024; 4(2):100258.
PMID: 38375189
PMC: 10875227.
DOI: 10.1016/j.xjidi.2024.100258.
GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy.
Deng F, Qiu Y, Zhang X, Guo N, Hu J, Yang W
Antib Ther. 2024; 7(1):77-87.
PMID: 38371956
PMC: 10873276.
DOI: 10.1093/abt/tbad032.
A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023.
Wei J, Zheng H, Dai S, Liu M
Heliyon. 2024; 10(2):e23929.
PMID: 38312701
PMC: 10835268.
DOI: 10.1016/j.heliyon.2023.e23929.
Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies.
Singh R, Chandley P, Rohatgi S
Immunohorizons. 2023; 7(12):886-897.
PMID: 38149884
PMC: 10759153.
DOI: 10.4049/immunohorizons.2300102.
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment.
Guo X, Wu Y, Xue Y, Xie N, Shen G
Front Immunol. 2023; 14:1291836.
PMID: 38106416
PMC: 10722299.
DOI: 10.3389/fimmu.2023.1291836.
Engineering therapeutic monoclonal antibodies.
Stone Jr C, Spiller B, Smith S
J Allergy Clin Immunol. 2023; 153(3):539-548.
PMID: 37995859
PMC: 11437839.
DOI: 10.1016/j.jaci.2023.11.018.
Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier.
Pardridge W
Front Drug Deliv. 2023; 3.
PMID: 37583474
PMC: 10426772.
DOI: 10.3389/fddev.2023.1227816.
Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.
Chen J, Zhu T, Jiang G, Zeng Q, Li Z, Huang X
Mol Cancer. 2023; 22(1):131.
PMID: 37563723
PMC: 10413520.
DOI: 10.1186/s12943-023-01830-x.
Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform.
Jack Borrok M, Li Y, Harvilla P, Vellalore Maruthachalam B, Tamot N, Prokopowitz C
Cancer Res Commun. 2023; 2(3):146-157.
PMID: 36874404
PMC: 9980914.
DOI: 10.1158/2767-9764.CRC-21-0150.
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.
Pang X, Huang Z, Zhong T, Zhang P, Wang Z, Xia M
MAbs. 2023; 15(1):2180794.
PMID: 36872527
PMC: 10012886.
DOI: 10.1080/19420862.2023.2180794.
ImmunoPET Directed to the Brain: A New Tool for Preclinical and Clinical Neuroscience.
de Lucas A, Lamminmaki U, Lopez-Picon F
Biomolecules. 2023; 13(1).
PMID: 36671549
PMC: 9855881.
DOI: 10.3390/biom13010164.
IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases.
Horner S, Moustafa-Oglou M, Teppert K, Hagelstein I, Kauer J, Pflugler M
Cancers (Basel). 2022; 14(16).
PMID: 36010934
PMC: 9405798.
DOI: 10.3390/cancers14163941.
Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies.
Stam J, de Maat S, De Jong D, Arens M, van Lint F, Gharu L
Sci Rep. 2022; 12(1):13413.
PMID: 35927444
PMC: 9352707.
DOI: 10.1038/s41598-022-15993-y.
Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.
Warmuth S, Gunde T, Snell D, Brock M, Weinert C, Simonin A
Oncoimmunology. 2022; 10(1):2004661.
PMID: 35844969
PMC: 9278964.
DOI: 10.1080/2162402X.2021.2004661.
Agonist antibody discovery: Experimental, computational, and rational engineering approaches.
Schardt J, Jhajj H, OMeara R, Lwo T, Smith M, Tessier P
Drug Discov Today. 2021; 27(1):31-48.
PMID: 34571277
PMC: 8714685.
DOI: 10.1016/j.drudis.2021.09.008.